Q1 EPS Estimate for Myriad Genetics Reduced by Analyst

Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) - Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Myriad Genetics in a note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.18) per share for the quarter, down from their prior forecast of ($0.08). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Myriad Genetics' current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics' Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.16) EPS.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). The company had revenue of $210.60 million for the quarter, compared to the consensus estimate of $210.35 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same period last year, the company earned ($0.12) EPS.

Several other brokerages have also recently weighed in on MYGN. UBS Group dropped their price target on shares of Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 25th. Craig Hallum started coverage on shares of Myriad Genetics in a research report on Wednesday, February 12th. They issued a "buy" rating and a $29.00 price target on the stock. Piper Sandler dropped their price target on shares of Myriad Genetics from $24.00 to $14.00 and set a "neutral" rating on the stock in a research report on Thursday, January 30th. Bank of America dropped their price target on shares of Myriad Genetics from $13.00 to $11.00 and set an "underperform" rating on the stock in a research report on Monday. Finally, Morgan Stanley dropped their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Monday, November 18th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $22.00.

Myriad Genetics Stock Down 3.2 %

Shares of MYGN stock traded down $0.34 on Friday, reaching $10.39. 1,038,495 shares of the company were exchanged, compared to its average volume of 1,176,442. Myriad Genetics has a one year low of $9.76 and a one year high of $29.30. The company has a market cap of $945.85 million, a price-to-earnings ratio of -7.99 and a beta of 1.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The company has a 50-day moving average of $13.21 and a 200-day moving average of $18.79.

Institutional Investors Weigh In On Myriad Genetics

Several large investors have recently modified their holdings of the stock. Atria Investments Inc increased its stake in shares of Myriad Genetics by 5.4% during the 3rd quarter. Atria Investments Inc now owns 11,414 shares of the company's stock worth $313,000 after purchasing an additional 581 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Myriad Genetics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company's stock worth $87,000 after buying an additional 583 shares during the period. Creative Planning boosted its holdings in Myriad Genetics by 9.8% in the 3rd quarter. Creative Planning now owns 9,949 shares of the company's stock worth $273,000 after buying an additional 892 shares during the period. Point72 Hong Kong Ltd bought a new position in Myriad Genetics in the 3rd quarter worth approximately $32,000. Finally, Point72 Asia Singapore Pte. Ltd. boosted its holdings in Myriad Genetics by 43.8% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company's stock worth $132,000 after buying an additional 1,471 shares during the period. Hedge funds and other institutional investors own 99.02% of the company's stock.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.